HOME >> MEDICINE >> NEWS
Gene mutations predict which lung cancers will respond to Iressa

Researchers from the Massachusetts General Hospital (MGH) Cancer Center have discovered a molecular marker that identifies lung cancer patients whose tumors will respond to treatment with the drug Iressa (gefitinib). Their findings, which will be published in the May 20 New England Journal of Medicine, are being released online today to coincide with the online release by Science of related research from Dana-Farber Cancer Institute.

"This discovery will help us significantly improve the treatment of many lung cancer patients and is also an important next step in the molecular targeting of cancer drugs," says Daniel Haber, MD, PhD, director of the MGH Cancer Center and senior author of the NEJM paper. "We're hopeful that what we have learned will eventually lead to more new drugs that will target tumor-specific mutations without affecting normal tissues."

Iressa was approved a year ago for the treatment of advanced non-small-cell lung cancer (NSCLC), a tumor that is particularly difficult to treat and is the leading cause of cancer deaths in the U.S. In a major clinical trial Iressa caused tumors to shrink significantly in only 13.6 percent of patients, but some of those responses were rapid and dramatic. As a result, the FDA approved the drug because there are no other treatment options for NSCLC patients for whom standard chemotherapy has failed.

Iressa acts by disabling the epidermal growth factor receptor (EGFR) on the surface of lung cancer cells, halting a sequence of signals that can lead to the uncontrolled growth characterizing a malignant tumor. In their search for an answer to why the drug worked so well for some NSCLC patients but was of no assistance to others, the MGH team screened tumor samples from MGH patients who participated in the Iressa clinical trial to search for mutations in the EGFR gene.

Initial analysis found mutations affecting the same area (the ATP cleft of the kinase domain) of the receptor prot
'"/>

Contact: Sue McGreevey
smcgreevey@partners.org
617-724-2764
Massachusetts General Hospital
29-Apr-2004


Page: 1 2 3

Related medicine news :

1. Non-invasive and invasive breast cancers share the same genetic mutations
2. Both inherited traits and tumor mutations affect response to treatment of leukemia
3. Small increases or blips in HIV levels do not signal mutations leading to drug-resistant HIV
4. Gene mutations responsible for childhood cataracts discovered
5. Breast cancer patients with BRCA1 or 2 mutations twice as likely to have double mastectomy
6. Breast cancer patients with BRCA 1/2 mutations twice as likely to choose double mastectomy
7. Mayo Clinic researchers discover gene mutations that ignore stress, lead to heart failure
8. In 15 seconds, new test will ID presence of 25 most common mutations of cystic fibrosis
9. Northwestern on trail of gene mutations that trigger sex reversal
10. Gene mutations found that lead to prostate cancer in mice new mouse model developed to study the disease
11. New evaluation tool reliably predicts recovery from coma

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Gene mutations predict which lung cancers will respond Iressa

(Date:5/29/2015)... New York, NY (PRWEB) May 29, 2015 ... readers on the “beauty of protection”. Skin Health ... through USA Today within the markets of New York, ... reach an estimated 750,000 readers. Its digital counterpart will ... online content hubs. To read more the Skin Health ...
(Date:5/29/2015)... Shaila Jiwa, a physiotherapist from Burnaby ... stated in a new announcement that patients of urinary ... commonly seen as a tabooed topic to talk about ... like Shaila Jiwa try to encourage people to come ... is a condition that can be classified under two ...
(Date:5/29/2015)... University, the first cannabis college in America, will return to Las ... demanded Basic and Advanced Classic Seminars on June ... each day. Certification is available upon completion of the seminars and ... 14 from 12:00 pm to 6:00 pm. Both the seminars and ... Casino in downtown Las Vegas. , Seminar topics covered ...
(Date:5/29/2015)... 29, 2015 The Croatia Cosmetic ... a long-lasting impression on what modern dentistry options are ... on a mission to revolutionize the perception of a ... high-class Wellness & Spa. , The top dental ... successful medical tourism agencies and led by ...
(Date:5/29/2015)... 2015 Healthpointe’s electromyography and nerve ... Los Angeles County clinics including its newest clinic ... being offered at all Healthpointe locations throughout Southern ... Bernardino County. , As the muscles contract, ... electrical impulses throughout the body and dictate whether ...
Breaking Medicine News(10 mins):Health News:Mediaplanet Launches “Skin Health” Campaign Featuring Colorescience 2Health News:Patients of Urinary Incontinence Should Not "Hide And Suffer," States Physiotherapist from Burnaby Physiotherapy Clinic 2Health News:Oaksterdam University to Host Educational Cannabis Seminars and Job Fair in Las Vegas June 12 to 15; Training For Those Wanting To Work in Legal Cannabis Industry 2Health News:Oaksterdam University to Host Educational Cannabis Seminars and Job Fair in Las Vegas June 12 to 15; Training For Those Wanting To Work in Legal Cannabis Industry 3Health News:Croatian Cosmetic Dentistry Providers New Approach to Revolutionize Cosmetic Dentistry 2Health News:Croatian Cosmetic Dentistry Providers New Approach to Revolutionize Cosmetic Dentistry 3Health News:Healthpointe Is Now Offering EMG and NCV Diagnostics at All Clinics throughout Southern California. 2
(Date:5/29/2015)... 29, 2015 LifeNet Health plans to enlarge ... 2015 to more than 160 people. The ... LifeNet Health,s innovative bio-implants, which are being made more ... be served. It also is a reflection of the ... "The growth and success of LifeNet Health is a ...
(Date:5/29/2015)... May 29, 2015  Haemonetics Corporation (NYSE: HAE ... Operating Officer, will present at the JMP Securities Life ... on June 23 rd , 2015 at 11:30am Eastern ... Davies, presentation live via webcast at: http://wsw.com/webcast/jmp27/hae ... HAE ) is a global healthcare company dedicated to ...
(Date:5/29/2015)... May 29, 2015 Amgen (NASDAQ: ... pivotal Phase 3, global, randomized, placebo-controlled trials evaluating ... of secondary hyperparathyroidism (SHPT) in patients with chronic ... the primary endpoint, demonstrating that a greater proportion ... a greater than 30 percent reduction in parathyroid ...
Breaking Medicine Technology:LifeNet Health to add more than 160 jobs in 2015 2Amgen Presents Pooled Phase 3 AMG 416 Data For The Treatment Of Secondary Hyperparathyroidism In Patients With Chronic Kidney Disease 2Amgen Presents Pooled Phase 3 AMG 416 Data For The Treatment Of Secondary Hyperparathyroidism In Patients With Chronic Kidney Disease 3Amgen Presents Pooled Phase 3 AMG 416 Data For The Treatment Of Secondary Hyperparathyroidism In Patients With Chronic Kidney Disease 4Amgen Presents Pooled Phase 3 AMG 416 Data For The Treatment Of Secondary Hyperparathyroidism In Patients With Chronic Kidney Disease 5Amgen Presents Pooled Phase 3 AMG 416 Data For The Treatment Of Secondary Hyperparathyroidism In Patients With Chronic Kidney Disease 6Amgen Presents Pooled Phase 3 AMG 416 Data For The Treatment Of Secondary Hyperparathyroidism In Patients With Chronic Kidney Disease 7
Cached News: